Actively Recruiting
Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
Led by Baker Heart and Diabetes Institute · Updated on 2025-05-31
685
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors \>55 years old with chemotherapy \>5 years ago. The overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.
CONDITIONS
Official Title
Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of cancer more than 10 years ago
- Have received potentially toxic chemotherapy including Anthracycline (any dose), Trastuzumab (Herceptin) in breast cancer with HER2 mutation, Tyrosine kinase inhibitors (e.g., sunitinib), or left chest radiotherapy
You will not qualify if you...
- Ejection fraction less than 50% at baseline echocardiogram
- Valvular stenosis or regurgitation of more than moderate severity
- History of previous heart failure with baseline New York Heart Association classification greater than 2
- Systolic blood pressure less than 110 mmHg
- Pulse less than 60 per minute if not on beta blockers
- Inability to obtain interpretable images from baseline echocardiogram
- Contraindications to beta blockers or angiotensin-converting enzyme inhibitors
- Life expectancy less than 12 months due to oncologic or other medical conditions, including pregnancy
- Already taking both angiotensin converting enzyme inhibitors/angiotensin receptor blockers and beta blockers, or intolerance/allergy to both
- Unable to provide written informed consent to participate in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Baker Heart and Diabetes Institute
Melbourne, Victoria, Australia, 3004
Actively Recruiting
Research Team
J
Joel Smith
CONTACT
T
Thomas H Marwick, MD,PhD,MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here